Prostate Cancer News on BioPortfolio

MagForce MF6 US NanoTherm IDE approval a major milestone

Edison Investment Research Pharmaceutical & healthcare MagForce MagForce has received IDE approval to start its first pivotal clinical trial evaluating NanoTherm focal ablation therapy for prostate cancer in the US. This is a major milestone for the ...

E3 Ubiquitin Protein Ligase XIAP Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2. Pipeline Review H1 2018 Report Updated 20022018 Price

E3 Ubiquitin Protein Ligase XIAP Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2. Pipeline Review H1 2018SummaryAccording to the recently pu...

CostEffectiveness of PSA Screening

A simulation model shows that the only costeffective strategy is a 4year screening interval with routine use of active surveillance for lowrisk prostate cancer.

Advaxis Prices $20.0 Million Public Offering of Common Stock

Advaxis Inc.ÂNASDAQADXS a latestage biotechnology company Advaxis or the Company focused on the discovery development and commercialization of cancer immunotherapies announced today the pricing of its previously announced unde...

LIDDS presenterar bokslutskommunik 2017

BOKSLUTSKOMMUNIK 2017Â FJRDE KVARTALET OKTOBER DECEMBER 2017Â Nettoomsttningen uppgick till 04 00 KSEKÂ Kostnaderna uppgick till 25 21 MSEKÂ Resultatet fre och efter skatt uppgick till 22 21 MSEKÂÂÂÂÂÂÂÂÂÂ Â Resultat per aktie uppgick till 011 ...

Pages